


FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 12-2004)		ATTORNEY'S DOCKET NUMBER BDM-06-1215
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.51) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/587874</div>
INTERNATIONAL APPLICATION NO. PCT/FR2005/000222	INTERNATIONAL FILING DATE 02 February 2005 (02.02.05)	PRIORITY DATE CLAIMED 02 February 2004 (02.02.04)
TITLE OF INVENTION ANGIOGENESIS INHIBITORS, COMPOSITIONS CONTAINING SAME AND USE THEREOF FOR TREATING DISEASES RELATED TO ANGIOGENETIC DEREGLATION		
APPLICANT(S) FOR DO/EO/US Danièle Mathieu, Jamal Temsamani and Michel Kaczorek		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input type="checkbox"/> A preliminary amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information: 		

U.S. APPLICATION NO. 10/587874		INTERNATIONAL APPLICATION NO. CT/FR2005/000222		ATTORNEY'S DOCKET NUMBER BDM-06-1215	
21. The following fees are submitted:					
<input checked="" type="checkbox"/> a) Basic national fee.....				\$ 300.00	\$ 300.00
<input checked="" type="checkbox"/> b) Examination fee.....				\$ 200.00	\$ 200.00
<input checked="" type="checkbox"/> c) Search fee.....				\$ 400.00	\$ 400.00
TOTAL OF ABOVE CALCULATIONS =				\$ 900.00	\$ 900.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	Rate		
- 100 =	/50 =		x \$250.00	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims		18 - 20 =	0	x \$ 50.00	\$
Independent claims		3 - 3 =	0	x \$200.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$1,030.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					
SUBTOTAL =				\$1,030.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 130.00	
TOTAL NATIONAL FEE =				\$1,160.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
TOTAL FEES ENCLOSED =				\$1,160.00	
				Amount to be refunded:	\$
				Amount to be charged:	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1,160.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 50-2719 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2719. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
<p>SEND ALL CORRESPONDENCE TO:</p> <div style="text-align: right; margin-top: 20px;">  T. Daniel Christenbury, Reg. No. 31,750 </div>					
<p>Customer No. 035811, whose contact information is: IP Group of DLA Piper Rudnick Gray Cary US LLP One Liberty Place, Suite 4900 1650 Market Street Philadelphia, PA 19103 (215) 656-3381</p>					

10/587874

IAP5 Rec'd PCT/PTO 28 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : Customer No.: 035811
Examiner :
Serial No. :
Filed : Herewith
PCT No. : PCT/FR2005/000222
PCT Filed : February 2, 2005
Inventors : Danièle Mathieu
 : Jamal Temsamani
 : Michel Kaczorek
Title : ANGIOGENESIS INHIBITORS,
 : COMPOSITIONS CONTAINING
 : SAME AND USE THEREOF FOR
 : TREATING DISEASES RELATED TO
 : ANGIOGENETIC DEREGULATION

Docket No.: BDM-06-1215

Confirmation No.:

Dated: July 28, 2006

MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**37 CFR 1.10
EXPRESS MAIL CERTIFICATION**

"Express Mail" mailing label number: EV 548524513 US


Date of Deposit: July 28, 2006

DESCRIPTION OF CONTENTS: Postcard, \$1,160.00 Check, an Application Transmittal Letter, in duplicate, Form PTO-1390, in duplicate, an Application Data Sheet (1 page), and copies of the Request (4 pages), WO 2005/075509 A1 and the International Search Report, and Forms PCT/ISA/210 and 237.

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to **Mail Stop PCT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Leslie Hood

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

10/587874

IAP5 Rec'd PCT/PTO 28 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit :
Examiner :
Serial No. :
Filed : Herewith
PCT No. : PCT/FR2005/000222
PCT Filed : February 2, 2005
Inventors : Danièle Mathieu

Customer No.: 035811

Docket No.: BDM-06-1215

Confirmation No.:

Title : ANGIOGENESIS INHIBITORS,
: COMPOSITIONS CONTAINING
: SAME AND USE THEREOF FOR
: TREATING DISEASES RELATED TO
: ANGIOGENETIC DEREGLATION

Dated: July 28, 2006

APPLICATION TRANSMITTAL LETTER


MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We submit herewith for filing in the U.S. Patent and Trademark Office Form PTO-1390, in duplicate, an Application Data Sheet (1 page), copies of the Request (4 pages), WO 2005/075509 A1 and the International Search Report, and Forms PCT/ISA/210 and 237, and our check in the amount of \$1,160.00, comprising the official filing fee.

Respectfully submitted,


T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC:lh
(215) 656-3381